As demonstrated in a previous meta‐analysis, the combined predictive utility of PD‐L1 expression and TMB was associated predictive prognosis and was usually used as biomarkers of first‐ or second‐line immunotherapy in patients with NSCLC.25 Here, CD274 is linked to non-small cell lung carcinoma.